HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $7 price target.
August 07, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Karyopharm Therapeutics and maintained a $7 price target.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100